文献速递产科母胎医学

妊娠期精神兴奋剂使用相关的胎盘并发症

Placental Complications Associated With Psychostimulant Use in Pregnancy.
PubMed 文献 · Obstet Gynecol · 2017-01-01

基于2000至2010年医疗补助计划人群的队列研究,比较妊娠早期使用安非他明-右旋安非他明或哌甲酯单药治疗的孕妇与未暴露孕妇,发现精神兴奋剂使用与先兆子痫和早产风险轻度相对增加相关,绝对风险增加较小,作者认为有明显注意缺陷多动障碍(ADHD)的女性不应基于这些发现被建议暂停治疗。

要点

  • 妊娠早期使用精神兴奋剂与先兆子痫风险轻度升高相关(校正RR 1.29,95%CI 1.11-1.49)。
  • 妊娠晚期继续使用精神兴奋剂与早产风险升高相关(校正RR 1.30,95%CI 1.10-1.55)。
  • 作者认为绝对风险增加小,有明显ADHD的女性不应因此暂停治疗。

核心结论

  • 妊娠期精神兴奋剂使用与先兆子痫和早产的相对风险轻度增加相关,绝对风险增加较小,有明显ADHD的女性不应基于这些发现被建议暂停ADHD治疗。

研究设计与样本

  • 基于人群的队列研究,纳入2000至2010年医疗补助计划中孕妇及其活产新生儿。
  • 妊娠前半期接受安非他明-右旋安非他明或哌甲酯单药治疗的女性与未暴露女性比较。
  • 以非兴奋剂ADHD药物托莫西汀作为阴性对照暴露。
  • 妊娠20周后继续兴奋剂单药治疗的女性与停药者比较。
  • 采用倾向评分分层估计风险比和95%CI以控制混杂因素。

主要发现

  • 未暴露孕妇中,先兆子痫风险3.7%,胎盘早剥1.4%,小于胎龄儿2.9%,早产11.2%。
  • 妊娠早期兴奋剂暴露与先兆子痫校正RR 1.29(95%CI 1.11-1.49),胎盘早剥1.13(0.88-1.44),小于胎龄儿0.91(0.77-1.07),早产1.06(0.97-1.16)。
  • 妊娠后半期继续兴奋剂治疗与停药相比,先兆子痫校正RR 1.26(95%CI 0.94-1.67),胎盘早剥1.08(0.67-1.74),小于胎龄儿1.37(0.97-1.93),早产1.30(1.10-1.55)。
  • 托莫西汀与研究结局无关。

临床怎么用

  • 作者认为,有明显ADHD的女性不应基于这些发现被建议暂停ADHD治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether psychostimulants used to treat attention-deficit/hyperactivity disorder (ADHD) are associated with risk of adverse placental-associated pregnancy outcomes including preeclampsia, placental abruption, growth restriction, and preterm birth. METHODS: We designed a population-based cohort study in which we examined a cohort of pregnant women and their liveborn neonates enrolled in Medicaid from 2000 to 2010. Women who received amphetamine-dextroamphetamine or methylphenidate monotherapy in the first half of pregnancy were compared with unexposed women. We considered atomoxetine, a nonstimulant ADHD medication, as a negative control exposure. To assess whether the risk period extended to the latter half of pregnancy, women who continued stimulant monotherapy after 20 weeks of gestation were compared with those who discontinued. Risk ratios and 95% CIs were estimated with propensity score stratification to control for confounders. RESULTS: Pregnancies exposed to amphetamine-dextroamphetamine (n=3,331), methylphenidate (n=1,515), and atomoxetine (n=453) monotherapy in early pregnancy were compared with 1,461,493 unexposed pregnancies. Among unexposed women, the risks of the outcomes were 3.7% for preeclampsia, 1.4% for placental abruption, 2.9% for small for gestational age, and 11.2% for preterm birth. The adjusted risk ratio for stimulant use was 1.29 for preeclampsia (95% CI 1.11-1.49), 1.13 for placental abruption (0.88-1.44), 0.91 for small for gestational age (0.77-1.07), and 1.06 for preterm birth (0.97-1.16). Compared with discontinuation (n=3,527), the adjusted risk ratio for continuation of stimulant use in the latter half of pregnancy (n=1,319) was 1.26 for preeclampsia (0.94-1.67), 1.08 for placental abruption (0.67-1.74), 1.37 for small for gestational age (0.97-1.93), and 1.30 for preterm birth (1.10-1.55). Atomoxetine was not associated with the outcomes studied. CONCLUSION: Psychostimulant use during pregnancy was associated with a small increased relative risk of preeclampsia and preterm birth. The absolute increases in risks are small and, thus, women with significant ADHD should not be counseled to suspend their ADHD treatment based on these findings.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cohen JM, Hernández-Díaz S, Bateman BT, et al. Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstet Gynecol. 2017. PMID: 29112657. doi:10.1097/AOG.0000000000002362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。